What you should know:
1. RedHill and Salix entered into a licensing agreement in 2014 for the therapy, which is now in development.
2. The pill is a flavorless, solid oral preparation that eases patient burden and improves the likelihood of a successful outcome.
3. Researchers recently completed a phase 2A study of a past version of the pill, which concluded with 62 patients demonstrating comparable bowel preparation to traditional preparation solutions.
4. RedHill CEO Dror Ben-Asher said the reacquisition of RHB-106 aligned with the company’s commercial activities in the U.S.
More articles on surgery centers:
Supply chain tip of the week: Grow your ASC sustainably
How ASCs purchase devices, equipment: 3 insights
Supply chain tip of the week: Streamline supply consumption
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.